MET and hepatocellular carcinoma: This possibility was originally demonstrated on HGF/Met signaling dependent tumor progression, stimulated by two distinct activating mutations in the kinase domain of Met [Joffre et al., 2011] and shown recently also in a hepatocellular carcinoma (HCC) model [Hu et al., 2015].